You just read:

Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.

News provided by

Regen BioPharma, Inc.

Mar 02, 2017, 08:00 ET